Dow Jones Newswires: Enhertu significantly delayed breast cancer progression in trial, AstraZeneca says

Daily Trade

AstraZeneca PLC said Monday that its Enhertu drug significantly delayed metastatic breast cancer progression in a Phase 3 trial, reinforcing the results of a prior trial.

The Anglo-Swedish pharma giant
AZN,
+2.28%

said results from the Destiny-Breast02 Phase 3 trial of Enhertu–trastuzumab deruxtecan–showed the trial met the primary endpoint, demonstrating a significant and clinically meaningful improvement in progression-free survival in patients.

Enhertu is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo Ltd.

Write to Kyle Morris at [email protected]

Articles You May Like

You Don’t Have to Trade Every Single Day to Be Successful – Don’t Force It!
RWH005: Meet the Master w/ Aswath Damodaran
RWH002: Investing Wisely In An Uncertain World W/ Howard Marks
Apple’s Coronavirus Warning, Tesla Climbs, Walmart Earnings & A Strong Buy Chip Stock – Free Lunch
The Best Energy ETF Now?